

An Overview on Ethanopharmacological Profile of Bacopa Monniera

Dr. C.Girish*, Chandana Priya R, G Sindhu, T Usha Kiran, Prof Ch Appa Rao
S.V.U. College of Pharmaceutical Sciences, Sri Venkateshwara University, Tirupati - 517502. A.P, India.

Date of Submission: 28-06-2025

Date of Acceptance: 08-07-2025

ABSTRACT

Plants have long been used as medicines due to their therapeutic properties. They keep receiving a lot of attention due to their ability to cure both acute and long-term pathological conditions. Plant research has gained global attention in recent years. A substantial amount of data has been amassed to show the enormous potential of medicinal plants in a variety of medical systems. Bacopa monniera is one of the most beneficial medicinal herbs in Ayurvedic medicine. Bacopa monniera was found worldwide in marshes and warmer climates. In traditional medicine, it was commonly used to treat a variety of illnesses. Brahminic acid, D-mannitol, β -sitosterol, nicotine, herpestine, bacosides A, triterpenoid saponins, saponins A, B, and C, and pseudojubilogenin glycoside were among the alkaloids found in Bacopa monniera. Pharmacological studies revealed that Bacopa monniera had a wide range of pharmacological effects, including antioxidant, gastrointestinal, endocrine, anti-inflammatory, analgesic, hair growth promoting effect, and effects on the central nervous system like memory enhancement, antidepressant, anxiolytic, anticonvulsant, and antiparkinsonian activity.

Key Words: Bacopa monniera, Brahmi, Brahminic acid and Bacopasides

I. INTRODUCTION

Bacopa monniera, a member of the Scrophulariaceae family, is also referred to as Brahmi. (1) There are 56 species in the genus that live in tropical and subtropical areas. (2) It originates from Indochina, Sri Lanka, and India that grows along lakes and rivers. The Andaman and Nicobar Islands are home to it. It is present in every district in Kerala, the southernmost state of India. (3) It is an essential component of several medicines and traditionally used in India. It has numerous branches, tiny elliptical leaves, violet blooms, and it is a creeping herb. (4)

The first mention of Bacopa monniera dates back to the sixth century A.D. In writings like

the Sushruta Samhita, Athar-Ved, and Charaka Samhita as a medhyarasyana - class plant used to lessen mental impairments and hone intelligence. Bacopa monniera is a common ingredient in several Ayurvedic medicines recommended for cognitive impairment. In contrast to the potentially strong and addictive effects of commonly used psychostimulants, moderate and long-term treatment of Bacopa monniera seems to support rather than deplete neurons a finding consistent with 1400 years of Ayurvedic research.

It is used to treat a variety of nerve problems, as a brain tonic to improve learning, memory, and focus, and to relieve anxiety in patients; it is also used to treat skin disorders, digestive issues, and as an antiepileptic, analgesic, and antipyretic (5). Alkaloid brahmine, nicotine, herpestine, bacosides A[3-(α -L-arabinopyranosyl)-O- β -D-glucopyranoside-10,20-dihydroxy-16-keto-dammar-24-ene], triterpenoid saponins, saponins A, B, and C, betulinic acid, D-mannitol, stigmastanol, β -sitosterol, and pseudojubilogenin glycoside were all present in Bacopa monniera. Pharmacological studies revealed that Bacopa monniera had a wide range of pharmacological effects, including antioxidant, gastrointestinal, endocrine, antimicrobial, anti-inflammatory, analgesic, cardiovascular, and smooth muscle relaxant effects. It also had effects on the central nervous system, including memory enhancement, antidepressant, anxiolytic, anticonvulsant, and antiparkinsonian effects (6-14).

BOTANICAL DESCRIPTION

1. Synonyms

- i. English : water hyssanth, etc
- ii. Sanskrit : Brahmi, Tiktalonika
- iii. Tamil : Nir-P-Pirami, Piramiyam
- iv. Telugu : Sambrani Oku
- v. Hindi : Jalbuti, baam, jalmim, Nir Brahmi
- vi. Kanada : Jala Brahmi, Niru Brahmi
- vii. Manipuri : Brahmi Sak

- viii. Marathi : Brahmi, Jala Brahmi, Nir Brahmi
ix. Oriya : Brahmi, prusnipar

2. Taxonomy

- i. Kingdom : plantae
- ii. Division : Magnoliophyta
- iii. Class : Magnoliopsida
- iv. Order : Lamiales
- v. Family : Scrophulariaceae
- vi. Genus : bacopa
- vii. Species : bacopa monniera



Fig 1: Bacopa Monniera

Morphological characters of Bacopa Monniera plant parts:

Root: White in colour, cylindrical, 5 mm in diameter, longitudinally.

Stem: Glabrous, branches are growing vertically, and nodes and internodes are present. They are about 1-1.5 cm long and 3-4mm in diameter, pale yellowish-green.

Leaf: Simple, opposite, and decussate, sessile, spatulate in shape, 0.6-2.5cm in length and 3-8 in width, entire.

Flower: Pale blue or pinkish-white, solitary, axillary 0.6-3 cm in length., Corolla gamopetalous, stamens 4, didynamous, anthers two-celled, syncarpous ovary, two-chambered with many ovules, stigma bilobed.

Fruit: Glabrous capsule, 5 mm long, persistent calyx, pedicel 1-3 cm long, purplish when fresh.

Seed: Numerous, minute, <1cm wide, elliptical or regular.

Ethnobotanical uses of Bacopa monniera (Brahmi):

- a. Brahmi leaf juice enhances the neurological system and increases blood flow (15).
- b. One effective antioxidant for treating oxidative damage is Brahmi. Epilepsy, mental illnesses, and irritation are all alleviated (16).
- c. Gonorrhoea and other STDs are treated with a powdered Brahmi leaf and milk mixture.
- d. Elephantiasis is treated with ointment made from Brahmi root.
- e. Brahmi leaf extract is a neurological tonic with neuroprotective properties that relieves fever and jaundice.
- f. It is used to treat skin issues, spleen problems, anaemia, dyspepsia, and leprosy.
- g. It provides nutrients to hair and promotes the growth of longer, thicker hair (17).
- h. It's also applied to the treatment of tumours, dementia, and ulcers.
- i. When coupled with Tulsi, neem, and amla, Brahmi promotes the growth of nails, hair, and skin.

CHEMICAL CONSTITUENTS:

The beneficial chemical components which are present in bacopa monniera are alkaloids, saponins, glycosides, flavonoids, nicotine, herpestine, and important chemicals like bacosides and bacopa saponins. In addition to them bacosides X, II, A3, and C as well as bacopa saponins are also present. (18,19) It also contains serine, pseudojujubogen, betulinic acid, brahmine, herpestone, nicotine, alanine, aspartic acid, glutamic saponins A, B, and C, bacosides A and B, triterpenoid, saponins, stigmasterol, D-mannitol, and stigmasterol (20). One of the isolated bacoside combinations from Bacopa monniera is called bacoside A. Among its most significant components are bacosides A3, II, and C, as well as the isomer of bacosapinnin C called jujubogenin (21).




Fig:2 Structures of the chemical constituents of *Bacopa monnieri* plant

PHARMACOLOGICAL ACTIONS:

Central nervous effects:

1. Memory enhancement:

Animal behavioural research has demonstrated that *Bacopa* enhances motor learning, acquisition, and retention while delaying the extinction of recently learned behaviours (22). Using the forced swimming test (FST) and tail suspension test (TST) on mice, the antidepressant efficacy of *B. monnieri* methanol extract and various fractions was assessed. However, it was shown that bacosides improve the level of acetylcholine and the hypoxic environment, which may help anterograde memory and reduce anterograde experimental amnesia caused by scopolamine and sodium nitrite, respectively. Furthermore, bacosides prevented retrograde amnesia caused by BN52021, a platelet-activating factor receptor antagonist. This effect is likely the

result of bacosides increasing platelet activating factor production by raising the level of glutamate in the brain (23).

Bacopa seems to work in the brain through a variety of ways, all of which could help slow down the aging process related to cognitive loss. These comprise the following: (i) direct action that promotes cholinergic function; (ii) activity related to antioxidants (flavonoids); (iii) metal chelation; (iv) actions that reduce inflammation; (v) enhanced blood circulation; (vi) adaptogenic activity; and (vii) elimination of β -amyloid deposits. (24).

2. Anti-Depressant Activity:

Depression is a common, often fatal illness that affects a large number of people. It has reduced concentrations of norepinephrine, serotonin, and dopamine (25). Both the stress hormone and the hormonal balance of the body are

influenced by substances. Its leaf increases the brain's serotonin levels, which lower anxiety and uneasiness and promote relaxation (26,27). In the forced swim and learned helplessness tests, two of the most often used behavioral paradigms in animal models of depression, it was discovered to have strong antidepressant effects. In rodents, it was shown to have antidepressant efficacy equivalent to that of imipramine, a common antidepressant medication. Because of its antidepressant and anxiolytic properties, serotonin and gamma-aminobutyric acid (GABA) are thought to be involved in the mechanism of action.(31)

When evaluated on forced swimming and tail-suspension models in experimental animals, bacopasides A and B, bacopasides I and II, bacopasaponin C, and the extract of *Bacopa monniera* showed antidepressant action, but bacopaside VII showed no antidepressant activity at all (28-30).

3. Anxiolytic:

Additional studies have demonstrated the anxiolytic, depressive, anticonvulsive, and antioxidant properties of crude plant extract of *Bacopa monnieri*, or bacosides(32). As an adaptogen, *bacopa monniera* proved very successful in restoring rats' corticosterone levels after both acute and chronic stress. Moreover, it restored noradrenalin (NA), 5-HT, and DA to normal in the rat brain and hippocampal regions under both acute and long-term unpredictable stress (33). *Bacopa monniera* increased 5-hydroxytryptamine levels in the cerebral cortex, hypothalamus, and hippocampal regions while decreasing norepinephrine levels. Comparing the higher doses of *Bacopa monniera* extracts to lorazepam, a common anxiolytic medication from benzodiazepine group, revealed noticeably more anxiolytic effects (34).

4. Anti parkinsonism:

Bacopa monniera has demonstrated potential as an anti-Parkinsonian drug by reducing alpha synuclein aggregation, preventing dopaminergic neurodegeneration, and restoring lipid content in nematodes in pharmacological *Caenorhabditis elegans* models of Parkinson's disease(35).

5. Anticonvulsant:

Additionally, bacosides or crude plant extract of *Bacopa monniera* have demonstrated anticonvulsive activity (38). It had neuroprotective properties against glutamate-mediated

excitotoxicity during seizures and against cognitive impairment linked to epilepsy brought on by pilocarpine.(36) Several convulsive models, including strychnine- and maximal electroshock-induced convulsions in rats, hypoxic stress-induced convulsions in mice, and lithium-pilocarpine-induced status epilepticus, were used to assess the anticonvulsant activity of the ethanolic extract of *Bacopa monniera*. For every model examined, the ethanolic leaf extract demonstrated strong anticonvulsant efficacy with a mechanism of action like that of benzodiazepines (GABA agonist)(37).

6. Endocrine Effects:

Bacopa monniera increased T4 by 41% in mice. It is not activated, suggesting that the extract acts only on the epithelial level to promote T4 production and release, not on the conversion of T4 to T3. BMEs caused a reversible suppression of fertility and spermatogenesis. The treatment altered the somniferous tubules in mice and decreased sperm motility and viability as well as the quantity of spermatozoa in the cauda, epididymis, and testis (39).

7. Anti-Microbial Activity:

The antibacterial effectiveness of *Bacopa monniera* was tested against a variety of bacterial strains using ethanol, methanol, and chloroform. Chloroform, methanol, and ethanol extracts were used to analyse *Streptococcus pyrogens*, *Bacillus pumilus*, *Bacillus amyloliquefaciens*, *Salmonella typhi*, *Vulgarica*, *Micrococcus luteus*, *Aspergillus Niger*, *Bacillus megaterium*, and *Bacillus subtilis*. The bacteria's reaction to crude extracts varied based on the growth inhibition zone, the microorganisms, and the solvent (40,41).

8. Hair Growth-Promoting Activity:

Alcoholic extracts of *Emblica officinalis*, *Bacopa monniera*, *Cyperus rotundus*, or the full medication are used to make herbal hair oil. Using coconut oil as the base, each of the three herbs was produced separately and added to the hair oil in different amounts. Using hair length testing and healthy albino rats, the hair growth was compared to a standard minoxidil 2 percent ethanolic solution in a main skin irritation test. In terms of follicular size expansion and anagen phase prolongation, hair oil formulations fared better than the others (42-44).

9. Gastrointestinal Effects:

Both people and animals have had in vitro studies conducted on the effects of *Bacopa*

monniera on the gastrointestinal tract. Irritable bowel syndrome and other conditions causing spasms in the intestines may be beneficial for BME (45,46). The results indicate that calcium influx inhibition, which affects both receptor- and electrical impulse-mediated calcium channels in the cell membrane, is principally responsible for BME's spasmolytic impact on smooth muscles. Research on animals and in vitro has shown that BM might have a protective impact. It affects stomach ulcers both preventively and therapeutically (47,48).

10. Antioxidant activity:

Bacosides have the ability to control the activities of SOD (superoxide dismutase), P450, and Hsp70, enabling the brain to be ready to respond in stressful or other unfavourable situations (49). The alcoholic extract of *Bacopa monniera* demonstrated hepatoprotective properties against the morphine-induced drop in GSH levels and inhibition of antioxidant enzymes in rats. (50) With an IC₅₀ value of 0.739 mg/ml, the methanolic extract of *Bacopa monniera* demonstrated scavenging activity (5). The administration of bacoside-A preserved the levels of trace elements and enhanced the antioxidant status. In rats with fibrosarcoma, *Bacopa Monniera* extract increased antioxidant status, decreased lipid peroxidation rate, and decreased tumour development indicators (51).

11. Anti-inflammatory activity:

The triterpenoid and bacoside found in *Bacopa monniera* are responsible for the plant's anti-inflammatory properties. By regulating the release of pro-inflammatory mediators, it can reduce inflammation. Tumour necrosis factor- α and interleukin-6, two pro-inflammatory cytokines, were not produced in the fractions containing bacosides and triterpenoids (52).

II. DISCUSSION & CONCLUSION:

Bacopa monniera is a medicinal plant used to treat various kinds of diseases and it is mainly used to treat neurodegenerative disorders. It is widely used in ayurvedic medicine. The health benefits and nutritional contents of *Bacopa* contribute to the medicinal world. This plant has high medicinal and food applications and it also contributes to the Sustainable Development Goal of promoting good health and well-being. It grows alongside of lakes and rivers and found in many places in India. The main chemical

components, it contains alkaloids, saponins, glycosides, flavonoids, nicotine, herpestine, and important chemicals like bacosides and *Bacopa* saponins it is used to treat variety of diseases. Due to its high availability and important chemicals present in it, *Bacopa monniera* becomes the important source to treat various kinds of diseases.

REFERENCES:

- [1]. Devendra P., Patel S.S., Birwal P., Basu S., Deshmukh G., & Datir R. *Bacopa monniera* as a functional food ingredient in food processing industry. *Journal of Pharmacognosy and Phytochemistry*. 2018; 7(3): 189-194.
- [2]. Bammidi S.R., Volluri S.S., Chippada S.C., Avanigadda S and Vangalapati M. A review on pharmacological studies of *Bacopa monniera*. *J Chem Bio Phy Sci*. 2011;1(2): 250-259.
- [3]. Brendler T. *Medicinal and Aromatic Plants of Indian Ocean Islands*. Med pharm Scientific Publishers; 2004.
- [4]. Christopher C., Johnson A. J., Mathew P. J., & Baby S. *Bacopa monniera*, with high contents of Bacoside A and Bacopaside I, from southern Western Ghats in India. *Industrial Crops and Products*. 2017; 98: 76-81.
- [5]. Sundriyal A, Rawat D.S and Singh A.K. Tissue culture, phytochemical and pharmacological study of *Bacopa monniera*. *Asian Journal of Biochemical and Pharmaceutical Research* 2013;1(3): 243-260.
- [6]. Chopra R.N, Nayar L and Chopra I.C. *Glossary of Indian Medicinal Plants*; Vol 32, Council of Scientific and Industrial Research; New Delhi 1956.
- [7]. Avanigadda S and Vangalapati M. A Review on pharmacological studies of *Bacopa monniera*. *J Chem Bio Phy Sci* 2011;1(2): 250 – 259.
- [8]. Sastri M.S, Dhalla N.S and Malhotra C.L. Chemical investigation of *Herpestismonniera* Linn (Brahmi). *Indian J Pharmacol*. 1959; 21: 303-304.
- [9]. Chatterji N, Rastogi R.P and Dhar M.L. Chemical examination of *Bacopa monniera* Wettst: parti-isolation of chemical constituents. *India J Chem*. 1965; 3: 24-29.
- [10]. Garay S, Mahato S.B, Ohtani K and Yamaski K. Dammarane-type triterpenoid saponins

- from *Bacopa monniera* Phytochemistry. 1996; 42: 815-820.
- [11]. Chakravarty A.K, Sarkar T, Nakane T, Kawahara N, Masuda K and Shiojima K. Bacopaside I and II: two pseudojubilogenin glycosides from *Bacopa monniera* Phytochemistry .2001; 58: 553-556.
 - [12]. Chakravarty A.K, Sarkar T, Nakane T, Kawahara N and Masuda K. New Phenylethanoid glycosides from *Bacopa monniera*. Chem Pharm Bull. 2002; 50: 1616-1618.
 - [13]. Chakravarty A.K., Garai S, Masuda K, Nakane T and Kawahara N. Bacopasides III-IVP; three new triterpenoid glycosides from *Bacopa monniera*. Chem Pharm Bull .2003; 51: 215-217.
 - [14]. Avanigadda S and Vangalapati M. A Review on pharmacological studies of *Bacopa monniera*. J Chem Bio Phy Sci. 2011;1(2): 250 – 259.
 - [15]. Majumdar, et al. (2013). "Bacosides and Neuroprotection". Natural Products: 3639–3660. doi:10.1007/978-3-642-22144- 6_157. ISBN 978-3-642-22143-9.
 - [16]. Mukherjee A, Gombar V, Shamsi Y, Gupta M, Sinha S. Effectiveness of Brahmi in various illnesses: A review paper. 2017;3: 10.
 - [17]. Cheng C.L, Koo M.W. Effects of *Centella asiatica* on ethanol-induced gastric mucosal lesions in rats. 2000;67: 2647-2653.
 - [18]. Saran P. L, Damor H. I, Lodaya D. H, Suthar M. K, Kalariya K. A, and Roy S. Identification of potential accessions of *Bacopa monnieri* L. for herbage yield and bacosides A content. Industrial Crops and Products.2022;176, 1143-1148.
 - [19]. Kumar A, Ghosal S Effect of *bacopa monniera* on animal models of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. In pharmacology and Toxicology 4 .1999.
 - [20]. Devishree R.A, Kumar S, Jain A.R. Short term effect of *Bacopa monnieri* on memory- A brief review. J. Pharm.2017; 11:1447–1450.
 - [21]. M. Deepak, G. K. Sangli, P. C. Arun, A. Amit (January–February 2005). determination of the major saponin mixture bacoside A in *Bacopa monnieri* by HPLC. Phytochemical Analysis. 2005;16 (1): 24–29. doi:10.1002/pca.805. PMID 15688952.
 - [22]. Singh H.K and Dharwan B.N. Neuropsychopharmacological effects of the Ayurvedic nootropic *Bacopa monniera* Linn (Brahmi). Indian Journal of Pharmacology 1997; 29: S359-S365.
 - [23]. Kishore K and Singh M. Effect of bacosides, alcoholic extract of *Bacopa monniera* Linn. (brahmi), on experimental amnesia in mice. Indian J Exp Biol .2005; 43(7): 640-645.
 - [24]. Stough C.K, Pase M.P, Cropley V, Myers S. A randomized controlled trial investigating the effect of Pycnogenol and *Bacopa CDRI08* herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: The Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910). Nutrition Journal. 2012; 11(11): 2-9.
 - [25]. Scholfield C.N., Ingkaninan K., Srimachai S., Kamkaew N. Oral *Bacopa monnieri* is anti-hypertensive in rats chronically treated with L-NAME.2012; 25: 23-26.
 - [26]. Chatterjee T.K, Chakraborty A, Pathak M, Sengupta G.C(1992). Effects of plant extract *Centella asiatica* (Linn.) On cold restraint stress ulcer in rats.1992; 30: 889-891.
 - [27]. Nadkarni K. M (Indian materia medica); Dr. K.M Nadkarni's (Indian materia medica) with Ayurvedic, Unani-Tibbi, Siddha, allopathic, homeopathic, naturopathic & home remedies, appendices & indexes. Popular prakashan. 1996;1 (Vol. 1).
 - [28]. Sairam K., Dorababu M., Goel R.K., Bhattacharya S.K. Antidepressant activity of standardized extract of *Bacopa monniera* in experimental models of depression in rats. Phytomedicine 2002; 9:207-211.
 - [29]. Zhou Y, Shen Y.H, Zhang C and Su J. Triterpene saponins from *Bacopa monnieri* and their antidepressant effects in two mice models. J Nat Prod .2007; 70(4): 652-655.
 - [30]. Singh H.K, Srimal R.C, Srivastava A.K, Garg N.K and Dhawan B.N. Proceedings of the fourth conference on the neurobiology of learning and memory, California 17-20;1990:79.
 - [31]. Shader R.I, Greenblatt D.J. Pharmacotherapy of acute anxiety. Bloom F.E, Kupfer D.J, editors. Psychopharmacology: Fourth Generation of Progress. Raven Press. 1995; 1341-1348.
 - [32]. Reas S.K., Amee K and Paulose C.S. Glutamate receptor gene expression and binding studies in pilocarpine induced epileptic rat, neuroprotective role of *Bacopa*

- monnieri extract. *Epilep Behav* 2008; 12:54-60.
- [33]. Sheikh N, Ahmad A, Siripurapu K.B, Kuchibhotla V.K, Singh S and Palit G. Effect of *Bacopa monniera* on stress induced changes in plasma corticosterone and brain monoamines in rats. *J Ethnopharmacol*. 2007;111: 671-676.
- [34]. Bhattacharya S.K and Ghoshal S. Anxiolytic activity of a standardized extract of *Bacopa monniera*, an experimental study. *Phytomedicine* 1998; 5: 77-82.
- [35]. Jadia P, Khan A, Sammi S.R, Kaur S, Mir S.S and Nazir A. Anti-Parkinsonian effects of *Bacopa monnieri*, insights from transgenic and pharmacological *Caenorhabditis elegans* models of Parkinson's disease. *Biochemical Biophysical Research Communications* .2012; 413 (4): 605-610.
- [36]. Paulose C.S, Chathu F, Khan S.R and Krishnakumar A. Neuroprotective role of *Bacopa monnieri* extract in epilepsy and effect of glucose supplementation during hypoxia, glutamate receptor gene expression. *Neurochem*. 2008; 33 (9): 1663-1671.
- [37]. Kaushik D, Tripathi A, Tripathi R, Ganachari M and Khan S.A. Anticonvulsant activity of *Bacopa monniera* in rodents. *Brazilian Journal of Pharmaceutical Sciences*. 2009; 45(n): 643-649.
- [38]. Reas S.K, Ameer K and Paulose C.S. Glutamate receptor gene expression and binding studies in pilocarpine induced epileptic rat, neuroprotective role of *Bacopa monnieri* extract. *Epilep Behav*. 2008;12: 54-60
- [39]. Singh R. H, & Singh L. Studies on the anti-anxiety effect of the medhyharasayana drug Brahmi (*Bacopa monniera*Wettst.). *Res Ayur Siddha*.1980;1: 133-148.
- [40]. Bhattacharya S. K, & Ghosal S. Anxiolytic activity of a standardized extract of *Bacopa monniera*: an experimental study. *Phytomedicine*.1998; 5(2): 77-82.
- [41]. Joshi B.B, Patel M.G, Dabhi B, Mistry K.N. Vitro phytochemical Analysis and antimicrobial activity of crude extract of *Bacopa monniera*. *Bull Pharm Med Sci (Bopams)* .2013;1(2):128-31.
- [42]. Jain P.K. Herbal drugs used for treating hair disease. *Pharm Clin Res* 2016;9(1):75-7.
- [43]. Jain P.K, Dass D.J. Hair growth potential of some traditional Herbs. *Pharm Clin Res* .2015;8(6):150-152.
- [44]. Jain P.K, Joshi H and Dass D.J. Drug that causes hair loss and promotes hair Growth – A review. *Res Pharm Biomed Sci*. 2012;3(4):1476-1482.
- [45]. Rao C.V, Sairam K, Goel R.K. Experimental evaluation of *Bacopa monniera* on rat gastric ulceration and secretion. *PhysiolPharmacol* .2000;44(4):435-441.
- [46]. Dharmani P, Palit G. Exploring Indian medicinal plants for antiulcer activity, *Pharmacology*. 2006;38(2):95-99.
- [47]. Goyal R. K, & Sairam K. Anti-ulcer drugs from indigenous sources with emphasis on *Musa sapientum*, *Tamrabhasma*, *Asparagus racemosus* and *Zingiber officinale*. *Indian Journal of Pharmacology*.2002; 34(2): 100.
- [48]. Sairam K, Rao C. V, Babu M. D, & Goel R. K. Prophylactic and curative effects of *Bacopamonnierain* gastric ulcer models. *Phytomedicine*.2001; 8(6): 423-430.
- [49]. Chowdhuri D.K, Parmar D, Kakkar P, Shukla R, Seth P.K, and Srimal R.C. Antistress effects of bacosides of *Bacopa monnieri*: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. *Phytotherapy Research* 2002;16(7):639-645.
- [50]. Sumathy T, Subramanian S, Govidasamy S and Balakrishna K.G. Protective role of *Bacopa monniera*on morphine induced hepatotoxicity in rats. 2001; 15: 643-645.
- [51]. Rohini G, Sabitha K.E and Devi C.S. *Bacopa monniera*Linn. extract modulates antioxidant and marker enzyme status in fibrosarcoma bearing rats. *Indian J Exp Biol*. 2004; 42(8):776-780.
- [52]. Viji V and Helen A. Inhibition of pro-inflammatory mediators: role of *Bacopa monniera* (L.) Wettst, *Inflammo pharmacology* 2010.